Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Department of Plastic Surgery and Hand Surgery, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Arch Gynecol Obstet. 2021 Feb;303(2):521-531. doi: 10.1007/s00404-020-05841-7. Epub 2020 Oct 29.
Symptomatic macromastia causes physical and psychological problems that can lead to restrictions in the patients' social and working lives and a reduced quality of life. Associated medical treatments also have a considerable impact on health-care costs. Several studies have assessed these costs, but the total disease costs of macromastia have never been evaluated on the basis of real-world data.
The data for 76 patients who underwent reduction mammoplasty between 2008 and 2016 were collected using a two-part questionnaire (preoperative and postoperative), as well as the patient files. Topics surveyed, besides demographic data, included physician visits, medical imaging, medical procedures, medical treatments, rehabilitation and convalescent measures, drug intake, medical aids, exercise activity, and sick leave days before surgery, to calculate the costs per year of conservative treatment of symptomatic macromastia.
The mean time from start of symptoms to surgery was 11.82 years. The data for this group of patients with symptomatic macromastia show that costs per patient amount to €1677.55 per year. These costs include medical consultation, radiological imaging, medical treatments and procedures, physical therapy and rehabilitation, medication, special brassieres, exercise classes costs for sick leave due to problems with macromastia, and travel expenses.
These results show that considerable health-care costs arise due to macromastia with conservative treatment. Overall, macromastia costs €1677.55 per patient/year. In particular, lost productivity due to sick days and the costs of physiotherapy are factors driving the high costs.
症状性巨乳症会导致身体和心理问题，从而限制患者的社交和工作生活，并降低生活质量。相关的医疗治疗也会对医疗保健成本产生重大影响。已经有几项研究评估了这些成本，但从未根据实际数据评估巨乳症的总疾病成本。
使用两部分问卷（术前和术后）以及患者档案收集了 2008 年至 2016 年间接受缩乳术的 76 名患者的数据。除了人口统计学数据外，调查的主题还包括医生就诊、医学影像、医疗程序、医疗治疗、康复和疗养措施、药物摄入、医疗辅助器具、运动活动以及手术前的病假天数，以计算每年保守治疗症状性巨乳症的成本。
从症状开始到手术的平均时间为 11.82 年。该组有症状性巨乳症的患者数据显示，每位患者的成本为每年 1677.55 欧元。这些费用包括医疗咨询、影像学检查、医疗治疗和程序、物理治疗和康复、药物、特殊胸罩、因巨乳症问题导致的病假运动课程费用以及旅行费用。
这些结果表明，由于保守治疗巨乳症会产生相当大的医疗保健成本。总体而言，巨乳症每位患者/年的成本为 1677.55 欧元。特别是，由于病假和物理治疗费用导致的生产力损失是导致高成本的因素。
